Clinical Oncology
Volume 21, Issue 7 , Pages 532-535 , September 2009

Radiochemotherapy in the Treatment of Breast Cancer

  • N.S. Bese

      Affiliations

    • Corresponding Author InformationAuthor for correspondence: N. S. Bese, Istanbul University, Cerrahpasa Medical School Department of Radiation Oncology, 34098 Istanbul, Turkey. Tel: +90-212-414-30-98; Fax: +90-212-414-30-01.

Received 31 March 2009 ,Accepted 23 April 2009.

References 

  1. Whelan T, Darby S, Taylor S, McGale P, Ewertz M. 2006 update of the Early Breast Cancer Trialists' Collaborative Group overview of radiation therapy for early breast cancer. ASCO Educational Booklet. 2007;3–6
  2. Danish Breast Cancer Cooperative Group , Nielsen HM, Overgaard M, Grau C, Jensen AR, Overgaard J. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol. 2006;24:2268–2275
  3. Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005;97:116–126
  4. Early Breast Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–1717
  5. Sartor CI, Peterson BL, Woolf S, et al. Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: Cancer and Leukemia Group B 9344. J Clin Oncol. 2005;23:30–40
  6. Park CC, Mitsumori M, Nixon A, et al. Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence. J Clin Oncol. 2000;18(8):1668–1675
  7. Huang J, Barbera L, Brouwers M, et al. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J Clin Oncol. 2003;21:555–563
  8. Recht A, Come SE, Henderson IC, et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med. 1996;33:1356–1361
  9. Bellon JR, Come SE, Gelman RS, et al. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial. J Clin Oncol. 2005;23:1934–1940
  10. Fisher B, Bryant J, Dignam JJ, et al. National Surgical Adjuvant Breast and Bowel Project. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol. 2002;20:4141–4149
  11. Sanguinetti G, Del Mastro L, Guenzi M, et al. Impact of chemotherapy dose-density on radiotherapy dose-intensity after breast conserving surgery. Ann Oncol. 2001;12:373–378
  12. Ejlertsen B, Mouridsen HT, Jensen MB. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premenopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89. Acta Oncol. 2008;47:662–671
  13. International Breast Cancer Study Group . Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J Clin Oncol. 1996;14:1885–1894
  14. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node positive premenopausal women with breast cancer. N Engl J Med. 1997;337:956–962
  15. Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. J Am Med Assoc. 1995;15:542–547
  16. Arcangeli G, Pinnarò P, Rambone R, Giannarelli D, Benassi M. A phase III randomized study on the sequencing of radiotherapy and chemotherapy in the conservative management of early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2006;64:161–167
  17. Bellon JR, Shulman LN, Come SE, et al. A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduced-dose radiotherapy in patients with early-stage breast carcinoma. Cancer. 2004;100:1358–1364
  18. Livi L, Saieva C, Borghesi S, et al. Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for early breast carcinoma. Int J Radiat Oncol Biol Phys. 2008;71:705–709
  19. Isaac N, Panzarella T, Lau A, et al. Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma: a well tolerated adjuvant regimen. Cancer. 2002;95:696–703
  20. Montemurro F, Gatti M, Redana S, et al. Concurrent radiotherapy does not affect adjuvant CMF delivery but is associated with increased toxicity in women with early breast cancer. J Chemother. 2006;18:90–97
  21. Marenghi C, Guglielmini P, Verri E, et al. Impact of concurrent radiotherapy on chemotherapy total dose and dose intensity in patients with early breast cancer. Tumori. 2005;91:126–130
  22. Fiets WE, van Helvoirt RP, Nortier JW, van der Tweel I, Struikmans H. Acute toxicity of concurrent adjuvant radiotherapy and chemotherapy (CMF or AC) in breast cancer patients. A prospective, comparative, non-randomised study. Eur J Cancer. 2003;39:1081–1088
  23. National Institutes of Health Consensus Development Conference Statement . Adjuvant therapy for breast cancer. J Natl Cancer Inst. 2001;30(Suppl 13):5–11
  24. Macquart-Moulin G, Viens P, Genre D, et al. Concomitant chemoradiotherapy for patients with nonmetastatic breast carcinoma: side effects, quality of life, and organization. Cancer. 1999;85:2190–2199
  25. Serin D, Aimard L, Kirschers S, et al. Adjuvant combined radiochemotherapy: a feasibility study of a new strategy in stages I and II. Bull Cancer. 1997;84:247–253
  26. Toledano A, Azria D, Garaud P, et al. Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial. J Clin Oncol. 2007;25:405–410
  27. Toledano A, Garaud P, Serin D, et al. Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conserving surgery enhances late toxicities: long-term results of the ARCOSEIN multicenter randomized study. Int J Radiat Oncol Biol Phys. 2006;65:324–332
  28. Rouëssé J, de la Lande B, Bertheault-Cvitkovic F, et al. Breast Cancer Group. A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy vs standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results. Int J Radiat Oncol Biol Phys. 2006;64:1072–1080
  29. Kumpulainen EJ, Hirvikoski PP, Johansson RT. Long-term outcome of adjuvant chemotherapy cyclophosphamide, mitoxantrone, and fluorouracil in women with breast cancer. Acta Oncol. 2008;47:120–123
  30. Burstein HJ, Bellon JR, Galper S, et al. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for stage II or III breast cancer. Int J Radiat Oncol Biol Phys. 2006;64:496–504
  31. Ellerbroek N, Martino S, Mautner B, Tao ML, Rose C, Botnick L. Breast-conserving therapy with adjuvant paclitaxel and radiation therapy: feasibility of concurrent treatment. Breast J. 2003;9:74–78
  32. Hanna YM, Baglan KL, Stromberg JS, Vicini FA, Decker D. Acute and subacute toxicity associated with concurrent adjuvant radiation therapy and paclitaxel in primary breast cancer therapy. Breast J. 2002;8:149–153
  33. Rustogi A, Budrukkar A, Dinshaw K, Jalali R. Management of locally advanced breast cancer: evolution and current practice. J Cancer Res Ther. 2005;1:21–30
  34. Gaui MF, Amorim G, Arcuri RA, et al. A phase II study of second-line neoadjuvant chemotherapy with capecitabine and radiation therapy for anthracycline-resistant locally advanced breast cancer. Am J Clin Oncol. 2007;30:78–81
  35. Kao J, Conzen SD, Jaskowiak NT, et al. Concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trials. Int J Radiat Oncol Biol Phys. 2005;61:1045–1053
  36. Kosma L, Koukourakis M, Skarlatos J, et al. Hypofractionated radiotherapy with 5-fluorouracil radiosensitization for locally ‘far advanced’ breast cancer. Am J Clin Oncol. 1997;20:562–566
  37. Carlson RW, Allred DC, Anderson BO, et al. Breast cancer. J Natl Compr Canc Netw. 2009;7:122–192
  38. Gakwaya A, Kigula-Mugambe JB, Kavuma A, et al. Cancer of the breast: 5-year survival in a tertiary hospital in Uganda. Br J Cancer. 2008;99:63–67

PII: S0936-6555(09)00141-1

doi: 10.1016/j.clon.2009.04.005

Clinical Oncology
Volume 21, Issue 7 , Pages 532-535 , September 2009

Article Tools